United States

Federal Trade Commission v Actavis Inc

570 U.S. 136 (2013)

JurisdictionUnited States

Year2013

Statusunclear

Key Principle

Reverse payment patent settlements between brand-name and generic drug manufacturers are subject to antitrust scrutiny under the rule of reason.

competition

ACCC v Yazaki Corporation [2018] FCAFC 73; (2018) 262 FCR 243

Get a detailed analysis of Federal Trade Commission v Actavis Inc and how it applies to your situation.